stockrowKeros Therapeutics, Inc.
KROSKeros Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $244.1 million, up 6,775.0% from fiscal 2024.
- Revenue
- +120.2%
- EPS
- +494.4%
- Free cash flow
- +6.87%
Quarter to September 2026, against a year earlier
Follow KROS
Alert me
Keros Therapeutics, Inc. (KROS) EV/Sales
As of 6 November 2026, Keros Therapeutics, Inc. (KROS) trades at a EV/Sales of −1.3×. Over the past ten years it has ranged from −50.7× (February 2025) to 6,139× (September 2024); the current reading is higher than 9% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.9× | (79.08%) |
| FY2024 | 9.2× | (80.12%) |
| FY2023 | 46.4× | 2.51% |
| FY2021 | 45.2× | — |
| FY2019 | −0.5× | — |
| FY2018 | −0.5× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | −0.6× | — |
| Mar 2026 | −2.0× | — |
| Dec 2025 | 1.9× | — |
| Sep 2025 | −0.2× | — |
| 14 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RNA Atrium Therapeutics, Inc. compare | −4.3× |
| BCYC Bicycle Therapeutics PLC Sponsored ADR compare | −2.3× |
| KROS Keros Therapeutics, Inc. | −1.3× |
| PYXS Pyxis Oncology, Inc. compare | n/m |
| CGEN Compugen Ltd. compare | 0.8× |
| PRQR ProQR Therapeutics N.V. compare | 1.1× |
| TRDA Entrada Therapeutics, Inc. compare | 3.6× |
| ACOG Alpha Cognition Inc. compare | 9.2× |
| IFRX InflaRx N.V. compare | 1,845× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)